AABB has developed a fact sheet for clinicians considering the use of COVID-19 convalescent plasma that reflects the changes in the Food and Drug Administration’s revised emergency use authorization for CCP issued Dec. 28. The fact sheet provides recently updated information about the qualification of high-titer CCP, which patient populations are eligible to receive CCP, and the new option for outpatient treatment with CCP.
Information about CCP and the revised EUA for blood centers is available in AABB’s Jan. 14 CCP toolkit.